¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"carrier mediated diffusion"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® carrier ÇÑ±Û º¸±ÕÀÚ, º¸ÃæÀÚ, º¸ÀÎÀÚ, ³ª¸£°³
¼³¸í   
  1. Áõ»ó¾øÀ̠ü³»¿¡ º´¿ø¹Ì»ý¹°ÀÌ Á¸ÀçÇÏ¿© °¨¿°ÀüÆÄÀÚÀÇ ¿ªÇÒÀ» Çϴ °³Ã¼. ÀÌ·¯ÇÑ °³Ã¼¸¦ º¸±Õ»óÅÂ(carrier state)¶ó ºÎ¸£°í ÀÖ´Ù. 2. ³ª¸£°³. ¼¼Æ÷³»ÀÇ ¹°Áú·Î¼­ ÇѰ³ ¶Ç´Â µÎ°³ÀÇ ÀüÀÚ¸¦ ¹Þ¾Æ È¯¿øµÇ³ª ±× ÈÄ ´Ù½Ã »êÈ­µÉ ¼ö Àִ °Í. 3. º¸ÀÎÀÚ. º¸Åë¿°»öü¼ºÀ̵砼º¿°»öü¼ºÀ̵砰£¿¡ ±× Á¤»óÀÇ ´ë¸³À¯ÀüÀÚ¿Í ´õºÒ¾î ¿­¼ºÀ¯ÀüÀÚ¸¦ º¸À¯Çϴ °³Ã¼. 4. ¹æ»ç¼±Çп¡¼­ ´Ù¸¥ ¹°Áú ÃßÀûÀÚ¿Í °°ÀÌ »ç¿ëµÇ¸ç, È­ÇÐÀû ¹°¸®Àû ÀÛ¿ëÀ¸·Î ±× ÃßÀûÀÚ¸¦ ¿î¹ÝÇϴ ¹°Áú. 5. ¼¼Æ÷³»¸·À» ÅëÇÑ ¿î¼ÛÀÇ °æ¿ì¿Í °°ÀÌ ¾î¶² ¹°ÁúÀÌ °¡¿ª¼ºÀ¸·Î ºÎÂøÇϴ ºÐÀÚ.
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î¼º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • delayed cell-mediated reaction
    Áö¿¬¼¼Æ÷¸Å°³¹ÝÀÀ
  • enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªºÐ¼®(¹ý)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier
    º¸±ÕÀÚ, º¸ÃæÀÚ, º¸ÀÎÀÚ, ³ª¸£°³, ¿î¹Ýü
  • heterozygous carrier
    ÀÌÁ¾Á¢ÇÕº¸ÀÎÀÚ
  • diffusion
    È®»ê
  • simple diffusion
    ´Ü¼øÈ®»ê
  • diffusion time
    È®»ê½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³¿î¹Ý
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • complement-mediated
    µµ¿òü¸Å°³-
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¸Å°³¸é¿ª°áÇÌÁõÈıº
  • cell-mediated lympholysis test
    ¼¼Æ÷¸Å°³¸²ÇÁ±¸¿ëÇØ½ÃÇè
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-mediated cytotoxicity
    µµ¿òü°ü·Ã¼¼Æ÷µ¶¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amalgam carrier
    ¾Æ¸»°¨¼ö¼Û±â(¡­âÃáêÐï).
  • healthy carrier
    °Ç°­º¸±ÕÀÚ(ÊÙËÓË»Ëö). ±â»ý°Ç°­º¸ÃæÀÚ(ÊÙËÓ̧Ëö).
  • hemophiliac carrier
    Ç÷¿ìº´ÀÎÀÚº¸À¯ÀÚ.
  • hemophiliac carrier
    Ç÷¿ìº´ÀÎÀÚº¸À¯ÀÚ.
  • hepatitis,carrier state
    º¸±ÕÀÚ(ÜÁжíº)
  • heterozygous carrier
    ÀÌÁ¾Á¢ÇÕº¸À¯ÀÚ.
  • hod carrier s palsy
    Àâ¿ë ¿î¹ÝÀÚ ¸¶ºñ(íÚéÄê¡Úæíº Ýö).
  • hod carrier s palsy
    Àâ¿ë¿î¹ÝÀÚ¸¶ºñ(íÚéÄê¡Úæíº Ýö).
  • ADC (apparent diffusion coefficient)
    °Ñº¸±â È®»ê °è¼ö
  • Ficks law of diffusion
    ÇÈÀÇ È®»ê(üªß¤)¹ýÄ¢(ÛööÎ)
  • Oudins agar diffusion
    ¿ìµ­ ÇÑõȮ»ê¹ý
  • agar diffusion
    ÇÑõ(³»)È®»ê(¡­üªß¤).
  • agar diffusion method
    ÇÑõ(³»)È®»ê¹ý.
  • agar gel diffusion
    ÇÑõ°ÖÈ®»ê(ùÎô¸¡­üªß¤).
  • anisotropic diffusion
    ºñµî¹æ¼º È®»ê
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated diffusion
    ´ãü(¸Å°³) È®»ê.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier mediated transport
    ¿î¹Ýü¸Å°³ À̵¿
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³ °ú¹Î¹ÝÀÀ
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
  • cell mediated hypersensitivity
    ¼¼Æ÷¸Å°³ °ú¹Î¹ÝÀÀ
  • cell mediated immunity
    ¼¼Æ÷¼º¸é¿ª.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷(¸Å°³)¸é¿ª°áÇÌÁõÈıº.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷¼º¸é¿ª°áÇÌÁõÈıº.
  • cell mediated lympholysis
    ¼¼Æ÷¸Å°³ ¸²ÇÁ±¸¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷¸Å°³¼º ¹ÝÀÀ
  • cell mediated reaction
    ¼¼Æ÷¸Å°³¼º ¹ÝÀÀ.
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³ ¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity(CMC)
    ¼¼Æ÷¸Å°³¼º ¼¼Æ÷µ¶¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier
    º¸ÃæÀÚ
  • convalescent carrier
    ȸº¹±âº¸ÃæÀÚ
  • healthy carrier
    °Ç°­º¸ÃæÀÚ
  • permanent carrier
    ¿µ±¸º¸ÃæÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier-facilitated diffusion
    ij¸®¾î ÃËÁø È®»ê(õµòäüªß¤)
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • F-mediated transduction
    F¸Å°³(ØÚË¿) ÇüÁúµµÀÔ(û¡òõÓôìý)
  • intron-mediated recombination
    ÀÎÆ®·ÐÁß°³(ñéË¿) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • mediated transport
    ¸Å°³¼ö¼Û(ØÚË¿âÃáê)
  • passive mediated transport
    ¼öµ¿ ¸Å°³¿î¹Ý(áôÔÑØÚË¿ê¡Úæ)
  • prophage-mediated conversion
    ÇÁ·ÎÆäÀÌÁö ¸Å°³ Àüȯ(ØÚË¿ï®üµ)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ATP-ADP carrier
    ATP-ADP ¿î¹Ýü(ê¡Úõô÷)
  • biotin carboxyl carrier protein
    ¹ÙÀÌ¿Àƾ Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carboxyl carrier protein
    Ä«¸£º¹½Ç ¿î¹Ý´Ü¹éÁú(ê¡ÚæÓ±ÛÜòõ)
  • carrier
    "ij¸®¾î, ¿î¹Ýü(ê¡Úæô÷)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carrier
    ¹Ý¼ÛÆÄ, ij¸®¾î, º¸À¯ÀÚ, º¸±ÕÀÚ, ´ãü
  • healthy carrier
    °Ç°­º¸±ÕÀÚ, °Ç°­º¸ÃæÀÚ
  • ADC [=apparent diffusion coefficient]
    °Ñº¸±âÈ®»ê°è¼ö
  • anisotropic diffusion
    ºñµî¹æ¼ºÈ®»ê
  • apparent diffusion coefficient [=ADC]
    °Ñº¸±âÈ®»ê°è¼ö
  • column diffusion method
    ±âµÕÈ®»ê¹æ¹ý
  • diffusion
    È®»ê, ¹Ì»ê
  • diffusion coefficient
    È®»ê°è¼ö
  • diffusion equation
    È®»êµî½Ä
  • diffusion gradient pulse
    È®»ê°æ»çÆÞ½º
  • diffusion imaging
    È®»ê¿µ»ó
  • diffusion spectroscopy
    È®»êºÐ±¤¹ý
  • diffusion tensor imaging [=DTI]
    È®»êÅÙ¼­¿µ»ó
  • diffusion time
    È®»ê½Ã°£
  • diffusion weighted imaging [=DWI]
    È®»ê°­Á¶¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
AGD agar gel diffusion; agarose diffusion; alpha-ketoglutarate dehydrogenase
DP data processing; deep pulse; definitive procedure; degradation product; degree of polymerization; de...
ACP accessory conduction pathway; acid phosphatase; acyl carrier protein; American College of Pathologis...
BCCP biotin carboxyl carrier protein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AAC ADP-ATP carrier
ACP Acyl Carrier Protein
ACP Acyl-acyl carrier protein
acyl-ACP Acyl-acyl carrier protein
ADC Apparent Diffusion Coefficient
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carrier mediated transport
    ¿î¹Ýü ¸Å°³ À̵¿
  • aldosterone-mediated sodium
    ¾Ëµµ½ºÅ×·Ð Áß°³µÈ ³ªÆ®·ý
  • amalgam carrier
    ¾Æ¸»°¨ ¼ö¼Û±â
    ¹°··¹°··ÇÑ ¾Æ¸»°¨À» »èÁ¦ÇÑ ¿Íµ¿À̳ª Ʋ ¼ÓÀ¸·Î ¿î¹ÝÇϴµ¥ »ç¿ëÇÏ´Â µµ±¸.
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • bacteria carrier
    ¼¼±Õ º¸±ÕÀÚ
  • carrier
    º¸±ÕÀÚ, ij¸®¾î, º¸À¯ÀÚ, ´ãü, º¸Çè¾÷ÀÚ
    1. ÁúȯÀÇ ÀÓ»ó ¼Ò°ßÀº ¾øÀÌ Æ¯º°ÇÑ °¨¿° ÀÎÀÚ¸¦ °¡Áö°í ´Ù¸¥ »ç¶÷À» °¨¿°½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ´Â »ç¶÷. °Ç°­Çϰųª ȸº¹±â¿¡ ÀÖ´Â º¸±ÕÀÚÀÏ ¼ö ÀÖ´Ù. 2. Á¦±âµÈ ÀÌÀǸ¦ ÇØ°áÇØ Áְųª Ä¡·á¸¦ Á¦°øÇϱâ·Î µ¿ÀÇÇÑ Ä¡°ú Ä¡·á °è¾àÀÚ Ãø.
  • carrier specificity
    ¿î¹Ýü ƯÀ̼º
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell mediated lympholysis
    ¼¼Æ÷ ¸Å°³ ¸²ÇÁ±¸ ¿ëÇØ
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cell-mediated cytotoxicity
    ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
    Ç×ü ȤÀº lym
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • chronic carrier
    ¸¸¼º º¸±ÕÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
cell-mediated reaction Immunological reaction of the delayed type, involving chiefly T lymphocytes, important in host defense against infection, in autoimmune diseases, and in transplant rejection.
See: skin test.
(05 Mar 2000)
ambipolar diffusion <radiobiology> Diffusion process in which buildup of spatial charge creates electric fields which cause electrons and ions to leave the plasma at the same rate. (Such electric fields are self-generated by the plasma and act to preserve charge neutrality.)
(09 Oct 1997)
anomalous diffusion <radiobiology> Diffusion in most plasma devices, particularly tokamaks, is higher than what one would predict from understood causes. The observed, typical diffusion is referred to as anomalous because it has not yet been explained.
Anomalous diffusion includes all diffusion which is not due to collisions and geometric effects. While such effects were not understood when the term was coined, and most still are not, diffusion due to well-understood wave phenomena is still 'anomalous'. Classical diffusion and Neo-classical diffusion are the two well-understood diffusion theories, although neither is adequate to fully explain the observed anomalous diffusion.
See: entries for classical diffusion and neoclassical diffusion. Anomalous resistivity
(09 Oct 1997)
bohm diffusion <radiobiology> A rapid loss of plasma across magnetic field lines caused by microinstabilities. Theory formulated by the physicist David Bohm.
Semiempirical formula for the diffusion coefficient given by Bohm in 1946 (noted by Bohm, Burhop, and Massey, who were developing a magnetic arc for use in uranium isotope separation). Bohm diffusion was proposed (not derived from first principles) to scale as 1/B rather than the 1/B^2 scaling predicted by classical diffusion. A 1/B scaling results from assuming that particles diffuse across field lines at an optimum rate (effective collision frequency=cyclotron frequency). The 1/B scaling is observed (approximately) in most reactors.
See: diffusion, microinstabilities, field lines.
(09 Oct 1997)
gel diffusion Diffusion in a gel, as in the case of gel diffusion precipitin tests in which the immune reactants diffuse in agar.
See: immunodiffusion.
(05 Mar 2000)
gel diffusion precipitin tests Precipitin test's in which the immune precipitate forms in a gel medium (usually agar) into which one or both reactants have diffused; generally classified in two types, in one dimension, and in two dimensions.
Synonym: gel diffusion reactions.
(05 Mar 2000)
gel diffusion precipitin tests in one dimension Precipitin test's in which antigen solution and antibody incorporated in agar are layered in tubes, permitting effective diffusion in the vertical dimension; the antibody-containing agar may be overlaid directly with antigen solution (single (gel) diffusion in one dimension).
(05 Mar 2000)
gel diffusion precipitin tests in two dimensions Precipitin test's made in a layer of agar that permits radial diffusion, in both of the horizontal dimensions, of one or both reactants. Double (gel) diffusion in two dimensions (Ouchterlony test, technique, or method) incorporates antigen and antibody solutions placed in separate wells in a sheet of plain agar, permitting radial diffusion of both reactants; this method is widely used to determine antigenic relationships; the bands of precipitate that form where the reactants meet in optimal concentration are of three patterns, referred to as reaction of identity, reaction of partial identity (cross-reaction), and reaction of nonidentity.
(05 Mar 2000)
gel diffusion reactions Precipitin test's in which the immune precipitate forms in a gel medium (usually agar) into which one or both reactants have diffused; generally classified in two types, in one dimension, and in two dimensions.
Synonym: gel diffusion reactions.
(05 Mar 2000)
passive diffusion See: facilitated transport.
(05 Mar 2000)
classical diffusion <radiobiology> In plasma physics, diffusion due solely to scattering (collisions) of charged particles (with unlike charges) via electrical (Coulomb) interactions. (See also diffusion.)
(09 Oct 1997)
population diffusion coefficient <cell biology> Coefficient that describes the tendency of a population of motile cells to diffuse through the environment. Its use presupposes that the cells move in a random walk.
(18 Nov 1997)
neoclassical diffusion <radiobiology> In a magnetised plasma, _classical_ diffusion refers to transport of particles due to Coulomb collisions, taking the spiral orbits in the magnetic field into account. In a toroidal magnetic field, the actual rate of diffusive transport is much higher due to slow changes in the positions of the centres of the spirals, known as banana orbits.
This faster transport is called _neo-classical_. With very few exceptions the transport in toroidal devices is observed to be 10-100 times larger still, presumably due to small-scale turbulence. The observed transport is called _anomalous_ (although it actually is the normal state).
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • diffusion
    È®»ê
  • diffusion
    »êÆ÷;À¯Æ÷;º¸±Þ;»ê¸¸
  • diffusion index
    È®»ê Áö¼ö;°æ±â µ¿Çâ Áö¼ö
  • diffusion pump
    È®»ê Áø°ø ÆßÇÁ(°¡½ºÀÇ È®»êÀ» ÀÌ¿ëÇÏ¿© ³ôÀº Áø°øµµ¸¦ ¸¸µê)
  • gaseous diffusion
    ±âü È®»ê¹ý
  • carrier
    º¸±ÕÀÚ
  • air carrier
    Ç×°øÈ¸»ç;Ç×°ø±â
  • atomic carrier
    ¿øÀÚ·Â Ç×°ø ¸ðÇÔ
  • atonic carrier
    ¿øÀÚ·Â Ç×°ø¸ðÇÔ
  • car carrier
    (¼öÃâ¿ë)ÀÚµ¿Â÷ ¿î¹Ý¼±
  • carrier
    ¿î¹ÝÀÎ;¿ìÆíÁý¹è¿ø;½Å¹® ¹è´Þ¿ø;¿î¼Û¾÷ÀÚ;¿î¼Ûȸ»ç;¿î¹Ý ¼³ºñ;ÁüÆÇ(ÀÚÀü°Å µîÀÇ);Àü¿°º´ ¸Å°³Ã¼;º¸±ÕÀÚ;(À¯ÀüÀÚÀÇ)º¸ÀδÙ;Ç×°ø¸ðÇÔ;¼Ò¼Û±â;¿î¹Ý¼±;=CARRIER WAVE;¹è¼ö±¸;Çϼö·Î;´ãü;SHOPPING BAG
  • carrier bag
    =SHOPPING BAG
  • carrier nation
    ÇØ¿î±¹
  • carrier pigeon
    Àü¼­±¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á